ArticleEmerging infectious diseases2015
Consensus on the development of vaccines against naturally acquired melioidosis.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Virulence of Burkholderia pseudomallei Strains from Western Hemisphere and Africa in Mice.Emerging infectious diseases · 2026Article
- Vascular-associated bacterial burden and neuroinflammatory transcriptional responses observed in models of pneumonic plague.Frontiers in microbiology · 2026Article
- An outer membrane vesicle vaccine prevents lung pathology in a macaque model of pneumonic melioidosis.Nature communications · 2025Article
- Melioidosis vaccines: recent advances and future directions.Frontiers in immunology · 2025Review
- Virulence of Burkholderia pseudomallei ATS2021 Unintentionally Imported to United States in Aromatherapy Spray.Emerging infectious diseases · 2024Article
- LVS ΔmBio · 2024Article
- The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with AerosolizedAntibiotics (Basel, Switzerland) · 2023Article
- Glanders (IDCases · 2023Article
- Efficacy of Treatment with the Antibiotic Novobiocin against Infection withAntibiotics (Basel, Switzerland) · 2022Article
- Evaluating the Contribution of the Predicted Toxin-Antitoxin System HigBA to Persistence, Biofilm Formation, and Virulence in Burkholderia pseudomallei.Infection and immunity · 2022Article
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- Hcp1-loaded staphylococcal membrane vesicle vaccine protects against acute melioidosis.Frontiers in immunology · 2022Article
- Recent Progress inPathogens (Basel, Switzerland) · 2021Review
- Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines.NPJ vaccines · 2021Article
- BipD ofMicroorganisms · 2021Review
- Comparative virulence of three different strains of Burkholderia pseudomallei in an aerosol non-human primate model.PLoS neglected tropical diseases · 2021Article
- BpOmpW Antigen Stimulates the Necessary Protective T-Cell Responses Against Melioidosis.Frontiers in immunology · 2021Article
- Combating the great mimicker: latest progress in the development ofExpert review of vaccines · 2020Review
- Human Melioidosis.Clinical microbiology reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism's known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.